Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma

Anti-PD-L1 treatment results in functional remodeling of the macrophage compartment

(2019) Huizhong Xiong et al.   CANCER RESEARCH

Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL

(2018) Frank Vari et al.   BLOOD

PD-L1+ tumor-associated macrophages and PD-1+ tumor infiltrating lymphocytes predict survival in primary testicular lymphoma

(2018) Marjukka Pollari et al.   HAEMATOLOGICA

PD-L1+ tumor-associated macrophages and PD-1+ tumor infiltrating lymphocytes predict survival in primary testicular lymphoma

(2018) Marjukka Pollari et al.   HAEMATOLOGICA

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma

(2018) Nicholas Meti et al.   Cancers

T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma

(2018) Suvi-Katri Leivonen et al.   HAEMATOLOGICA

Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers

(2018) Takefumi Komiya et al.   Frontiers in Oncology

IDO1: An important immunotherapy target in cancer treatment

(2017) Fangxuan Li et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

(2017) Robert Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

(2017) Sydney R. Gordon et al.   NATURE

Checkpoint Inhibition in Hodgkin Lymphoma - a Review

(2017) Paul J. Bröckelmann et al.   Oncology Research and Treatment

Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma

(2016) Baoping Guo et al.   BMC Medicine

Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance

(2016) Donatella Aldinucci et al.   CANCER LETTERS

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

(2016) S. Vardhana et al.   HAEMATOLOGICA

Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma

(2016) Manuel Gotti et al.   HEMATOLOGICAL ONCOLOGY

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

(2016) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

(2016) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

(2016) Anas Younes et al.   LANCET ONCOLOGY

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

(2016) S. Vardhana et al.   HAEMATOLOGICA

Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment

(2015) Emanuele Cencini et al.   HEMATOLOGICAL ONCOLOGY

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma

(2015) Young Wha Koh et al.   TUMOR BIOLOGY

Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study

(2014) Ji-Young Choe et al.   BMC CANCER

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

(2014) George C. Prendergast et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Programmed death-1 pathway in cancer and autoimmunity

(2014) Ariel Pedoeem et al.   CLINICAL IMMUNOLOGY

CD163 Expression Was Associated with Angiogenesis and Shortened Survival in Patients with Uniformly Treated Classical Hodgkin Lymphoma

(2014) Young Wha Koh et al.   PLoS One

The classical Hodgkin lymphoma tumor microenvironment: macrophages and gene expression-based modeling

(2014) D. W. Scott et al.   Hematology-American Society of Hematology Education Program

CD68 tumor-associated macrophage marker is not prognostic of clinical outcome in classical Hodgkin lymphoma

(2013) Smita Kayal et al.   LEUKEMIA & LYMPHOMA

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial

(2012) K. L. Tan et al.   BLOOD

Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma

(2012) B. Sanchez-Espiridion et al.   HAEMATOLOGICA

Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma

(2011) D. Azambuja et al.   ANNALS OF ONCOLOGY

Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment

(2011) Christian Steidl et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma

(2010) P. Kamper et al.   HAEMATOLOGICA

Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma

(2010) Christian Steidl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome

(2008) B. Chetaille et al.   BLOOD